The Specialist Forum Volume 13 No 11 November 2013 | Page 85

Zuvamor

®

March 2013
Dear Healthcare Provider,
AstraZeneca Pharmaceuticals and Aspen are pleased to announce the launch of Zuvamor® (rosuvastatin), making the
original rosuvastatin more accessible to patients.
Zuvamor® is indicated for patients with primary hypercholesterolaemia, mixed dyslipidaemia and isolated
hypertriglyceridaemia or familial hypercholesterolaemia, either alone or as an adjunct to diet and other lipid
lowering treatments. 1
Please see below for prices approved by the Department of Health:

Nappi code

Product Name

Active
Ingredient

Strength

Pack Size

Dosage Form

NEW SEP
(ex VAT)

717520001

Zuvamor® 10

Rosuvastatin

10 mg

28

Tabs

R 138.41

717521001

Zuvamor® 20

Rosuvastatin

20 mg

28

Tabs

R 200.35

717522001

Zuvamor® 40

Rosuvastatin

40 mg

28

Tabs

R 243.51

Should you require more information, please contact Claude Hadebe [phone] or our Medical Hotline on
Should you require more information, please contact Lindi Kekana on on [phone] or our MedicalHotline on
0800 118 088.
0800118 088.
Kind Regards,

Kind Regards,

Lindi Kekana
Claude Hadebe

Saras Rosin
Senior Marketing Business Development
AstraZeneca Pharmaceuticals

Head of Marketing: Pharma
Commercial Manager:
Aspen Pharmacare
Cardiovascular Portfolio Marketing
Aspen Pharmacare
Reference: 1. Zuvamor® approved package insert.

S4 Zuvamor® 10. Reg. No: 36/7.5/0353; Zuvamor® 20. Reg. No: 36/7.5/0354; Zuvamor® 40. Reg. No: 36/7.5/0355. Each tablet contains 10 mg, 20 mg or 40 mg of rosuvastatin respectively as rosuvastatin
calcium. For further details please refer to the package insert approved by the medicines regulatory authority. Applicant: AstraZeneca Pharmaceuticals (Pty) Limited. Co. Reg. No./Nr. 1992/005854/07,
5 Leeuwkop Road, Sunninghill, 2157. Marketed by: Aspen Pharmacare. Building 12, Healthcare Park, Woodlands Drive, Woodmead, 2191. Medical Information Hotline [phone].
A 16079 03/13. ZUM 03/13/002.

Page 26

July 2013 | The Specialist Forum